References

1. Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anaemia of chronic kidney disease. Kidney Int Suppl 2021;11(1):8-25 doi10.1016/j.kisu.2020.12.002

2. Singh AK, Carroll K, McMurray JJV Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. New Eng J Med 2021;385(25):2313-2324 doi 10.1056/NEJMoa2113380

3. Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, et al. Desidustat in anaemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND). Am J Nephrol 2022;53(5):352-360 doi 10.1159/000523961

4. Shutov E, Sulowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3,randomized, double-blind, placebo controlled study (ALPS). Nephrol Dial Transplant. 2021;36:1629–1639

5. Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6:624–635

6. Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol.2021;32:737–755 133

7. Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36:1616–1628

8. Chertow GM, Pergola PE, Farag YMK, et al. Vadadustat in patients with anemia and non dialysis-dependent CKD. N Engl J Med. 2021;384:1589–1600

9. Singh AK, Carroll K, Perkovic V, et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med. 2021;385:2325–2335

10. Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021;36:1717–1730

11. Csiky B, Schomig M, Esposito C, et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3,  randomized, open-label, active controlled study (PYRENEES). Adv Ther. 2021;38:5361–5380

12. Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol. 2022;33:850–866

13. Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of roxadustat in anemia of  kidney failure: SIERRAS study. Kidney Int Rep. 2021;6:1829–1839

14. Eckardt KU, Agarwal R, Aswad A, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384:1601–1612

15. Ku E, del Vecchio L, Eckardt K-U, Haase VH, Johansen KL, Nangaku M, et al. Novel anemic therapis in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney In 2023 doi 10.1016/j.kint.2023.05.009  [preprint accessed online 10/6/2023]

16. US Food and Drug Administration. Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients not on dialysis and on dialysis. FDA Presentation: Cardiovascular and Renal Drugs Advisory Committee Meeting, July 15, 2021. Available from https://www.fda.gov/media/150756/download [accessed online 10/6/2023]

17. Buchholz B, Eckardt K-U. Role of oxygen and the HIF-pathway in polycystic kidney disease. Cell Signal 2020;69:109524 doi 10.1016/j.cellsig.2020.109524

18. Zheng Q, Wang Y, Yang H, Sun L, Zhang P, Zhang X, et al. Cardiac and kidney adverse effects of HIF Prolyl-Hydroxylase Inhibitors for anemia in patients with CKD not receiving dialysis: a systematic review and meta-analysis. Am J Kidney Dis 2023;81(4):434-445.e1 doi 165 10.1053/j.ajkd.2022.09.014

19. Rashid M, Zadeh LR, Baradaran B, Molavi O, Ghesmati Z, Sabzichi M, et al. Up-down regulation of HIF-1α in cancer progression. Gene 2021;25(798):145796 doi 168 10.1016/j.gene.2021.145796

20. Haase VH. The VHL tumour suppressor: master regulator of HIF. Curr Pharm Des.2009;15(33):3895-3903 doi 10.2174/138161209789649394

21. Zhang D, Lv F-L, Wang G-H. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. Eur Rev Med Pharmacol Sci 2018;22(16):5071-5076 doi 173 10.26355/eurrev_201808_15699

22. Rath G, Aggarwal R, Jawanjal P, Tripathi R, Batra A. HIF-1 alpha and placental growth factor in pregnancies complicated with preeclampsia: a qualitative and quantitative analysis. J Clin Lab Anal 2016;30(1):75-83 doi 10.1002/jcla.2819

---

South African Nephrology Society (SANS). Consensus Statement on the Use of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors (HIF-PHIs). South African Nephrology Society; 2023.